# of Displayed Technologies: 2 / 2

Applied Category Filter (Click To Remove): Diseases and Disorders


Overcoming Immune Checkpoint Inhibition with VISTA Deficient NK Cells – ViDe* NK Cells
TS-000972 — Natural Killer (NK) cells express a range of receptors to activate or inhibit certain cellular behavior to kill cancer cells. When an NK cell is deficient or dysfunctional, the efficiency of the NK cells is severely limited. VISTA is a protein sequence that activates T cells and acts as a moderator for the immune system. It has low-to-moderate expression but has been the target of study by a team of researchers at Nationwide Children’s Hospital led by Dr. Dean Lee. By removing VISTA in expanded NK cells, the inhibitory signal will be eliminated and thus resulting in an enhanced ability of NK cells to target cancers and overcome the immune-suppressive signals for improved cancer immunotherapy.
  • College:
  • Inventors: Lee, Dean; Pereira, Marcelo
  • Licensing Officer: Corris, Andrew

Priming Peptide Pools for Isolation of SARS-CoV-2-Specific T Cells
TS-000913 — Peptides can be used to stimulate antigen-specific T cells, allowing activated T cells to be isolated from immune individuals to be used in vaccination or treatment in others. The novel disease Coronavirus, also denoted as 2019-nCoV, was recognized by the World Health Organization as an unknown etiology in December of 2019. Severe Acute Respiratory Syndrome (SARS) is a disease that presents flu-like symptoms that is caused by coronavirus (SARS-CoV). A current process widely applicable to many pathogens uses the Miltenyi Prodigy device. In a study led by Dr. Dean Lee, his team found that this process can be adapted to SARS-CoV-2 using a specialty mix of peptides to isolate T cell immunity.
  • College:
  • Inventors: Lee, Dean
  • Licensing Officer: Corris, Andrew

Loading icon